# Phase 1 Audit — Does the Current Prototype Match Phase 1?

## Verdict

**Yes, the current prototype mostly matches Phase 1 development.**

It is already suitable as a hackathon MVP because it shows:

- A dashboard landing view.
- A dataset upload / demo dataset flow.
- Ranked mutation signals.
- Drug-repurposing shortlist.
- Explainability panel.
- Research-use boundary.
- Report preview.
- Architecture/workflow page.
- Local deterministic mock-data logic.

This is aligned with Phase 1 because Phase 1 should not attempt real clinical prediction, real quantum computation, real hospital deployment, or regulated diagnostic claims.

## What is already strong

### 1. Research-use positioning is clear
The sidebar and report pages repeatedly state that outputs are research-use hypotheses requiring expert review and validation. This is important because the product should avoid day-one diagnostic claims.

### 2. The flow is coherent
Current flow:

Dashboard → Analysis → Results → Report → Architecture

This is clear for a hackathon judge and supports a live pitch demo.

### 3. The prototype is feasible
It uses local mock data and deterministic ranking logic. This is correct for Phase 1 because the hackathon is testing business thinking and product clarity, not production-grade biomedical AI.

### 4. The architecture page is honest
The prototype says the hybrid compatibility layer is simulated/prototype. This protects the team from quantum-hype criticism.

### 5. The biological examples are reasonable
Genes shown such as EGFR, TP53, KRAS, BRCA1, and ALK are credible oncology-related genes. Pathways such as EGFR/ERBB signalling, p53 tumour suppressor pathway, RAS/MAPK signalling, homologous recombination DNA repair, and ALK tyrosine kinase signalling are reasonable for a research demo.

## What does not fully match the intended Phase 1 vision

### 1. Branding name mismatch
The UI currently says **BioQuantum Oncology** instead of **OncoQ.tech**.

Correction:
Use **OncoQ.tech** as the product/platform name.

Suggested sidebar wordmark:

```txt
ONCOQ
OncoQ.tech
```

or

```txt
ONCOQ.TECH
Hybrid Oncology Intelligence
```

Avoid switching between BioQuantum Oncology, OncoQ.tech, and OncoQ AI in the same prototype.

### 2. Visual impact is too flat for a winning pitch
The current UI is clean, but it lacks the premium Behance-level medical SaaS feel requested earlier:

- No central scientific / genomic visual.
- No 3D anatomical or DNA intelligence focus.
- No strong visual hero moment.
- Too much looks like a normal admin SaaS dashboard.

Correction:
Add a central “Genomic Intelligence Canvas” on the Dashboard.

Visual idea:

- Semi-transparent DNA helix / molecular network / human torso silhouette.
- Mutation markers around EGFR, TP53, KRAS, BRCA1, ALK.
- Floating labels and small analysis cards.
- Soft teal/cyan glow.
- Clear note: “Research-use cohort visualization, not patient diagnosis.”

### 3. Dashboard does not yet explain the product in one glance
The first dashboard communicates the concept, but a judge should instantly understand:

> Upload mutation dataset → rank mutation signals → rank drug-repurposing hypotheses → export evidence report.

Correction:
Add a compact pipeline visual at the top or center:

```txt
Dataset → Mutation Annotation → AI Ranking → Hybrid Compatibility Layer → Drug-Repurposing Report
```

### 4. Biological confidence language needs tightening
Terms such as “AI confidence” and “model accuracy” can sound like validated clinical AI. For Phase 1, use safer terms.

Replace:

- “AI confidence” → “Prototype relevance score”
- “Model accuracy” → “Benchmark target” or “Ranking agreement target”
- “Prediction” → “Research hypothesis ranking”
- “Cancer risk prediction” → “Mutation relevance / risk signal prioritisation”

### 5. Drug examples are too generic
“EGFR inhibitor class”, “MEK pathway inhibitor class”, and “PARP inhibitor class” are safe, but Phase 2 should include clearer evidence mapping.

Do not list actual drugs as treatment recommendations. If real examples are used, label them as literature/database research examples, not recommended treatments.

Safe Phase 1 wording:

```txt
EGFR inhibitor class — research candidate class
MEK pathway inhibitor class — pathway-level investigation candidate
PARP inhibitor class — DNA repair vulnerability hypothesis
```

### 6. Need provenance and limitation fields
The result table should show why the platform ranked something, but it should also show where the evidence category comes from.

Add columns/fields:

- Evidence category: Strong / Moderate / Emerging / Exploratory
- Evidence type: known oncogenic pathway / biomarker association / drug-target pathway match / literature-level hypothesis
- Limitation: requires retrospective validation / not sufficient for clinical action
- Next validation: confirm mutation call / benchmark against curated datasets / expert review

### 7. Need clearer customer mode
The UI should feel made for:

- oncology R&D teams
- cancer genomics units
- bioinformaticians
- biotech/pharma researchers

Not for:

- individual patients
- doctors prescribing treatment live
- hospital appointment users

Correction:
Use terms like:

- Cohort
- Dataset
- Biomarker
- Pathway
- Evidence report
- Research review
- Retrospective validation
- R&D workspace

Avoid:

- Patient activity
- Blood pressure
- Heart rate
- Appointment
- Medical dashboard
- Doctor treatment decision

## Phase 1 final target

By the end of Phase 1, the prototype should achieve this:

> A judge can open the site and understand in under 60 seconds that OncoQ.tech turns de-identified cancer mutation data into ranked mutation relevance signals and drug-repurposing hypotheses, with an honest research-use boundary and a clear commercial pilot story.
